{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:09Z","timestamp":1777870329456,"version":"3.51.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-02087-3","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:07:14Z","timestamp":1726729634000},"page":"2383-2387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lessons for the clinical nephrologist: legacy effects of bevacizumab and ramucirumab lead to nephrotic syndrome due to renal-limited thrombotic microangiopathy with podocytopathy"],"prefix":"10.1093","volume":"37","author":[{"given":"Takahide","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"issue":"11","key":"2087_CR1","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.2147\/OTT.S166151","volume":"21","author":"B Xiao","year":"2018","unstructured":"Xiao B, Wang W, Zhang D (2018) Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 21(11):5059\u20135074. https:\/\/doi.org\/10.2147\/OTT.S166151","journal-title":"Onco Targets Ther"},{"key":"2087_CR2","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381\u20131389. https:\/\/doi.org\/10.1681\/ASN.2010020167","journal-title":"J Am Soc Nephrol"},{"key":"2087_CR3","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I (2017) Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 28:2932\u20132942. https:\/\/doi.org\/10.1093\/annonc\/mdx514","journal-title":"Ann Oncol"},{"key":"2087_CR4","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1074\/jbc.C300012200","volume":"278","author":"H Sugimoto","year":"2003","unstructured":"Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278:12605\u201312608. https:\/\/doi.org\/10.1074\/jbc.C300012200","journal-title":"J Biol Chem"},{"key":"2087_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1159\/000510141","volume":"51","author":"YF Hu","year":"2020","unstructured":"Hu YF, Tan Y, Yu XJ, Wang H, Wang SX, Yu F, Zhao MH (2020) Podocyte involvement in renal thrombotic microangiopathy: a clinicopathological study. Am J Nephrol 51:752\u2013760. https:\/\/doi.org\/10.1159\/000510141","journal-title":"Am J Nephrol"},{"key":"2087_CR6","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.atv.17.11.2793","volume":"17","author":"JR Horowitz","year":"1997","unstructured":"Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM (1997) Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17:2793\u20132800. https:\/\/doi.org\/10.1161\/01.atv.17.11.2793","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2087_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","volume":"20","author":"R Yamada","year":"2019","unstructured":"Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K (2019) Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol 20:14. https:\/\/doi.org\/10.1186\/s12882-018-1194-9","journal-title":"BMC Nephrol"},{"key":"2087_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-239603","volume":"14","author":"Y Nakano","year":"2021","unstructured":"Nakano Y, Kumagai J, Nagahama K, Fujisawa H (2021) A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings. BMJ Case Rep 14:e239603. https:\/\/doi.org\/10.1136\/bcr-2020-239603","journal-title":"BMJ Case Rep"},{"key":"2087_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016236","volume":"98","author":"T Fujii","year":"2019","unstructured":"Fujii T, Kawasoe K, Tonooka A, Ohta A, Nitta K (2019) Nephrotic syndrome associated with ramucirumab therapy: a single-center case series and literature review. Medicine (Baltimore) 98:e16236. https:\/\/doi.org\/10.1097\/MD.0000000000016236","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02087-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02087-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02087-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:34Z","timestamp":1777564414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/8\/2383\/8306329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02087-3","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patient in this case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient provided written consent for their personal or clinical information to be published in this report, along with any accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The authors have declared that no conflict of interest exists.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not receive any financial support.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Takahide Iwasaki and Masataka Ikeda diagnosed and treated nephrotic syndrome. Akihiro Kuma and Makoto Yoshida diagnosed the renal pathology. Takahide Iwasaki drafted the manuscript. Akihiro Kuma, Masataka Ikeda, and Takahiro Kuragano revised the manuscript critically. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}